17 of 100
BACKNEXT
17. Alexion Pharmaceuticals
Alexion Pharmaceuticals

3-year average
Revenue Growth: 43%
Profit Growth: 34%
Total Return: 69%

This biopharmaceutical company is focused on treating two severe and ultra-rare disorders. Its lead product, Soliris, is the only drug approved for patients with an extremely rare and life-threatening blood disease referred to as PNH (paroxysmal nocturnal hemoglobinuria). Alexion reported $274 million worth of second-quarter sales of Soliris, up 48% from the same period last year. The company credited the growth to increasing numbers of patients being treated with the drug globally. It follows Soliris's approval in the U.S. and European Union late last year as the first and only treatment for patients with an ultra-rare genetic disease known as Atypical Hemolytic Uremic Syndrome (aHUS). -- N.S.

Get stock quote: ALXN
Revenue ($ millions): $862
Net Income ($ millions): $194
Sectors: Health Care
From the September 24, 2012 issue.

Northern Oil and Gas 237%
ZAGG 104%
Green Mountain Coffee Roasters 78%
Cirrus Logic 450%
IAMGOLD 421%
HFF 341%
Questcor Pharmaceuticals 120%
3D Systems 112%
TPC Group 111%
To qualify, a company -- domestic or foreign -- must be trading on a major U.S. stock exchange; file quarterly reports to the SEC; have a minimum market... More